ONKURE MANAGEMENT
ONKURE MANAGEMENT
Status:
Active
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-05-02 | OnKure Therapeutics | OnKure management investment in Series A - OnKure Therapeutics | 7 M USD |
More informations about "OnKure management"
Reneo Pharmaceuticals and OnKure Announce …
May 13, 2024 Management and Organization. Following the merger, the combined company will be led by Nicholas Saccomano, Ph.D., President and …See details»
OnKure Therapeutics Leadership Team
Aug 12, 2021 Prior to OnKure, he was the Chief Science Officer and Site Head at Pfizer’s Boulder facility, leading a team of 170 research scientists focused on small molecule drug …See details»
OnKure Therapeutics - Crunchbase Company Profile & Funding
OnKure is a clinical-stage biopharma company developing precision medicines targeting validated cancer drivers. New. ... Executive Management ... 3,464 Number of Organizations • $525.5B …See details»
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
May 13, 2024 In February 2024, OnKure initiated a first-in-human clinical trial to evaluate OKI-219, a mutant-selective PI3Kα H1047R inhibitor. The PIKture-01 trial is a Phase 1 dose …See details»
OnKure Announces Closing of Merger with Reneo ... - BioSpace
Oct 7, 2024 Following the reverse stock split and based on the final exchange ratios of 0.0236 shares of Reneo common stock for each share of OnKure common stock and 0.1448 shares …See details»
Reneo Pharmaceuticals Announces Stockholder Approval of …
Oct 3, 2024 The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead …See details»
OnKure and Reneo Pharmaceuticals complete merger
Oct 7, 2024 OnKure is engaged in the development of a suite of mutant-selective PI3Kα inhibitors, aiming to enhance treatment efficacy and safety. Its lead product candidate, OKI …See details»
Investor Relations - OnKure Therapeutics
Dec 10, 2024 OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences December 10, 2024 OnKure Announces Encouraging Preliminary Safety, …See details»
Reneo Pharmaceuticals和OnKure宣布拟议合并-动脉网 - vbdata.cn
May 13, 2024 OnKure及其董事和执行官，包括R.Michael Carruthers、Isaac Manke博士、Andrew Phillips博士，他们是OnKure董事会的非员工成员，Nicholas A.Saccomano博 …See details»
OnKure Therapeutics (OKUR) Investor Relations Material
Mar 9, 2025 Latest reports from OnKure Therapeutics Inc. Access all reports. Q4 2024. Q3 2024. Q2 2024. Reneo Pharmaceuticals Inc. is a clinical-stage pharmaceutical company …See details»
Company OnKure Therapeutics, Inc. - MarketScreener.com
3 days ago Business description: OnKure Therapeutics, Inc. OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the …See details»
OnKure Reports Q4 Results with $110.8M Cash Runway Through …
Mar 10, 2025 OnKure Therapeutics (NASDAQ: OKUR) ... The recently completed merger and $65 million financing provide organizational stability to execute on these ... business strategy …See details»
Highbridge Capital Management LLC Acquires Significant Stake in
The acquisition of OnKure Therapeutics shares has a notable impact on Highbridge Capital Management's portfolio. With OnKure now representing 0.48% of the portfolio, the firm holds a …See details»
OnKure Therapeutics Reports Fourth Quarter and Full Year
Mar 10, 2025 OnKure is currently developing OKI-219, a selective PI3Kα H1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple …See details»
OnKure Announces Closing of Merger with Reneo - GlobeNewswire
Oct 4, 2024 Following the reverse stock split and based on the final exchange ratios of 0.0236 shares of Reneo common stock for each share of OnKure common stock and 0.1448 shares …See details»
Who Owns OnKure Therapeutics – CanvasBusinessModel.com
Oct 2, 2024 As with any company, understanding the key shareholders or owners is essential to gaining insight into the organization's direction and priorities. ... Additionally, the founders and …See details»
OnKure Therapeutics Reports Progress on PIKture-01 Trial and
Mar 10, 2025 OnKure Therapeutics updates on PIKture-01 trial progress, ... which may indicate unsustainable cost management. ... contract manufacturers, and contract research …See details»
OnKure Therapeutics price target lowered to $30 from $35 at
Mar 11, 2025 Oppenheimer lowered the firm’s price target on OnKure Therapeutics to $30 from $35 but keeps an Outperform rating on the shares after its Q4 results.The firm’s post-earnings …See details»
OKUR - OnKure Therapeutics, Inc. (NasdaqGM) - Share Price and …
The average one-year price target for OnKure Therapeutics, Inc. is $34.88. The forecasts range from a low of $31.31 to a high of $42.00. A stock’s price target is the price at which analysts …See details»
Jones Trading sets OnKure stock Buy rating, $32 target
Jan 28, 2025 Tuesday, Jones Trading initiated coverage on OnKure Therapeutics Inc. (NASDAQ: OKUR) with a Buy rating and a price target of $32.00.Currently trading at $5.00, …See details»